Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults.
Duobrii
halobetasol propionate
plaque
psoriasis
tazarotene
topical
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
27
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients.
Identifiants
pubmed: 32606876
doi: 10.2147/CCID.S252426
pii: 252426
pmc: PMC7295208
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
391-398Informations de copyright
© 2020 Reddy et al.
Déclaration de conflit d'intérêts
Vidhatha Reddy, Eric Yang, and Bridget Myers have no disclosures or conflicts of interest to report. Tina Bhutani is currently an investigator for Celgene, Galderma, Janssen, and Regeneron. She has served as an advisor for Abbvie, Lilly, and Pfizer.
Références
J Am Acad Dermatol. 2003 May;48(5):760-7
pubmed: 12734506
J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8
pubmed: 16384751
J Drugs Dermatol. 2018 Aug 1;17(8):863-868
pubmed: 30124725
J Hypertens. 2013 Mar;31(3):433-42; discussion 442-3
pubmed: 23249828
J Am Acad Dermatol. 2017 Mar;76(3):377-390
pubmed: 28212759
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Br J Dermatol. 1996 Oct;135 Suppl 49:18-25
pubmed: 9035701
J Am Acad Dermatol. 2018 Aug;79(2):287-293
pubmed: 29614243
J Clin Aesthet Dermatol. 2018 Nov;11(11):15-19
pubmed: 30588269
J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1145-8
pubmed: 1757605
Nutr Diabetes. 2012 Dec 03;2:e54
pubmed: 23208415
J Am Acad Dermatol. 2014 Mar;70(3):512-6
pubmed: 24388724
J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1153-6
pubmed: 1757607
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):919-927
pubmed: 30134735
Arch Dermatol. 2010 Aug;146(8):891-5
pubmed: 20713823
J Drugs Dermatol. 2019 Oct 01;18(10):1012-1018
pubmed: 31584780
J Drugs Dermatol. 2019 Mar 01;18(3):279-284.
pubmed: 30909333
Acta Derm Venereol Suppl (Stockh). 1989;151:7-10; discussion 47-52
pubmed: 2533778
J Am Acad Dermatol. 1998 Oct;39(4 Pt 2):S139-43
pubmed: 9777792
N Engl J Med. 2005 May 5;352(18):1899-912
pubmed: 15872205
J Drugs Dermatol. 2019 Mar 01;18(3):297-299
pubmed: 30909352
JAMA. 2006 Oct 11;296(14):1735-41
pubmed: 17032986
JAMA Dermatol. 2013 Jan;149(1):84-91
pubmed: 23407990
J Drugs Dermatol. 2017 Mar 1;16(3):197-204
pubmed: 28301614
J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1149-52
pubmed: 1757606
J Drugs Dermatol. 2018 Dec 01;17(12):1290-1296
pubmed: 30586261
J Drugs Dermatol. 2018 Jul 1;17(7):723-726
pubmed: 30005093
J Am Acad Dermatol. 2019 Jan;80(1):282-285
pubmed: 30227193
J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S18-24
pubmed: 9270552